TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01835951

Intervention type: OTHER
Group type: OTHER
Intervention: Grouped Debriefing
Description: Debriefing consists in an analysis by the investigator of the management of the anaesthesia crisis simulated in the presence of all the subjects included in the Groupe Debriefing group.

Intervention type: OTHER
Group type: OTHER
Intervention: Individual Debriefing
Description: Individual debriefing consists in a individual meeting between each subject of the study and the investigator to analyze the management of the anaesthesia crisis simulated.
Study: NCT02015676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Initial loading does of 4 mg/kg IV, followed by 2 mg/kg IV weekly, until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Initial loading does of 4 mg/kg IV, followed by 2 mg/kg IV weekly, until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 60 mg/m\^2 IV weekly; dose increased to 70 mg/m\^2, and subsequently 80 mg/m\^2, after 2 treatment cycles with no evidence of DLT until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 60 mg/m\^2 IV weekly; dose increased to 70 mg/m\^2, and subsequently 80 mg/m\^2, after 2 treatment cycles with no evidence of DLT until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myocet
Description: 40 mg/m\^2 IV weekly; dose increased to 50 mg/m\^2 IV after 2 treatment cycles with no evidence of DLT for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myocet
Description: 40 mg/m\^2 IV weekly; dose increased to 50 mg/m\^2 IV after 2 treatment cycles with no evidence of DLT for 6 cycles
Study: NCT03272295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette with guaiacol
Description: Based on reference cigarette with added ingredient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette with liquorice extract powder
Description: Based on reference cigarette with added ingredient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette plus I-menthol
Description: Based on reference cigarette with added ingredient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette with propylene glycol
Description: Based on reference cigarette with added ingredient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette with sorbitol
Description: Based on reference cigarette with added ingredient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette with multiple ingredients
Description: Based on reference cigarette plus propylene glycol, glycerol, liquorice extract powder, cocoa powder, carob bean extract, fig juice concentrate, maltol, guaiacol, geraniol, fenugreek extract.
Study: NCT01618162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: Injected subcutaneously (under the skin) once daily. Dose individually adjusted.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Injected subcutaneously (under the skin) once daily.
Study: NCT04603534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aged Simulation Suit
Description: The aged simulation suit (Sakamoto Model M716, Tokyo, Japan) will be worn by students. The simulation suit consist of a several items such as loads, a soft material band with Velcro, glasses, ear plugs, gloves, belts and a cane. All the items are need to simulate one's posture just like in elderly person. Small, medium and large sizes of suits are provided by the company thereby each suit is suitable for each student related to their wearing size. Prior to this study, a total of three sets of suits will be gathered. Then, each student will perform each pre-defined scenarios step by step after the suit is worn. During the activities no help or leading will be given to the students. However, one of the researchers will supervise the students during the activities so that to integrate a safe platform. In addition, each student will be informed that if he/she can terminate the activity whenever it is required.
Study: NCT03272295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette with multiple ingredients
Description: Based on reference cigarette plus propylene glycol, glycerol, liquorice extract powder, cocoa powder, carob bean extract, fig juice concentrate, maltol, guaiacol, geraniol, fenugreek extract.
Study: NCT00542009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CE-326,597 100 mg QD
Description: Administered orally, once daily with morning meal for duration of trial (84 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CE-326,597 50 mg QD
Description: Administered orally, once daily with morning meal for duration of trial (84 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CE-326,597 25 mg QD
Description: Administered orally, once daily with morning meal for duration of trial (84 days).
Study: NCT03321396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sodium alginate mixed with calcium lactate
Description: The product is used in Endoscopic submucosal dissection which is accomplished by steps listed as follows: lesion marking, submucosal injection, mucosal incision, submucosal dissection, then en-bloc resection. It's a new submucosal injection regimen, sodium alginate mixed with calcium lactate, which turned to calcium-alginate gel, we called it as Gut Guarding Gel.
Study: NCT00439868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WellbutrinXL
Description: WELLBUTRIN XL tablets will be available with dose strength of 150 and 300 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WellbutrinXL
Description: WELLBUTRIN XL tablets will be available with dose strength of 150 and 300 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching placebo tablets to WELLBUTRIN XL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching placebo tablets to WELLBUTRIN XL.
Study: NCT00273312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patupilone
Description: Patupilone was in dosage strength of 10 mg/4 mL as a clear, colorless concentrate for solution for injection in individual 10 mL glass vials
Study: NCT03386279

Intervention type: DRUG
Group type: OTHER
Intervention: PF-04965842
Description: one single dose of 600 mg by mouth

Intervention type: DRUG
Group type: OTHER
Intervention: PF-04965842
Description: one single dose of 600 mg by mouth

Intervention type: DRUG
Group type: OTHER
Intervention: PF-04965842
Description: one single dose of 600 mg by mouth

Intervention type: DRUG
Group type: OTHER
Intervention: PF-04965842
Description: one single dose of 600 mg by mouth

Intervention type: DRUG
Group type: OTHER
Intervention: PF-04965842
Description: one single dose of 600 mg by mouth

Intervention type: DRUG
Group type: OTHER
Intervention: PF-04965842
Description: one single dose of 600 mg by mouth

Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin
Description: one single dose of 400 mg by mouth

Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin
Description: one single dose of 400 mg by mouth

Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin
Description: one single dose of 400 mg by mouth

Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin
Description: one single dose of 400 mg by mouth

Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin
Description: one single dose of 400 mg by mouth

Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin
Description: one single dose of 400 mg by mouth

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: one single dose by mouth

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: one single dose by mouth

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: one single dose by mouth

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: one single dose by mouth

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: one single dose by mouth

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: one single dose by mouth
Study: NCT03871595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416
Description: 3 tablets with 10 milligram (mg) of BI 894416 (total: 30 mg) were administered as one single oral dose with 240 milliliter (mL) of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416
Description: 3 tablets with 10 milligram (mg) of BI 894416 (total: 30 mg) were administered as one single oral dose with 240 milliliter (mL) of water.
Study: NCT03385928

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Investigational product given within 2 hours of symptom onset
Study: NCT02115945

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DN4 test
Description: The DN4 test was used to evaluate neuropathic pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The SF 12 test
Description: The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The SF 12 test
Description: The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HAD scale
Description: The anxiety/depression scale (HAD) was used to assess anxiety and depression.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HAD scale
Description: The anxiety/depression scale (HAD) was used to assess anxiety and depression.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual analogue score
Description: Visual analogue score vas used to evaluate pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visual analogue score
Description: Visual analogue score vas used to evaluate pain.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: femoral block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: epidural block
Study: NCT03087461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and self-management
Description: The intervention will include aerobic exercise and self-management education using technology.
Study: NCT04090788

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dried bitter-gourd supplements
Description: intervention with 2.4g/d dried bitter-gourd supplements

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dried cucumber supplements
Description: reference intervention with 2.4g/d dried cucumber supplements
Study: NCT03038152

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Lymph Node Dissection
Description: Undergo targeted axillary lymph node dissection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Localization
Description: Undergo axillary lymph node localization

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Device
Description: Receive Magseed via ultrasound guided injection
Study: NCT02956720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UltraShape Power
Description: non-invasive body contouring procedure
Study: NCT00565981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: orally, 40 mg/m2 d1-3 q4w, x4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: subcutaneous, starting dose 3 mg and escalation to 10 mg, then 30 mg, followed by 30 mg thrice weekly for 16 weeks in escalated dose
Study: NCT03888833

Intervention type: DEVICE
Intervention: ECMO
Description: ECMO installation
Study: NCT02129374

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct repair of pars defect
Description: Direct repair at pars defect was performed with 4.5mm cortical screw in young spondylolytic patients.
Study: NCT01426256

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Bolus dose of 250,000 IU during hospitalization + maintenance dose of 50,000 IU vitamin D every other week to be initiated 3 months after bolus dose
Study: NCT03385928

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo given within 2 hours of symptom onset
Study: NCT01886898

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Infant formula
Description: infant formula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant formula
Description: infant formula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant formula
Description: infant formula

Intervention type: OTHER
Group type: OTHER
Intervention: Breastfeeding
Study: NCT04650555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO 300 Oral Powder
Description: Amorphous solid dispersion of genistein milled into a powder
Study: NCT01077206

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: 80mg daily versus 40mg daily, for 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: 80mg daily versus 40mg daily, for 21 days.
Study: NCT01828255

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish®
Study: NCT01118728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study: NCT02410252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iThermonitor
Description: The device is a continuous temperature monitoring tool for home monitoring of temperature. Participants are asked to use this device for two weeks.
Study: NCT02972411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voluntary ventilatory response
Description: Training of the subjects for voluntary increase in the respiratory minute ventilation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Acetazolamide 125mg. PO every 12 hours since 24 hours before ascent, until 48 hours at high altitude
Study: NCT02611284

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LISA
Description: All infants were supported with nCPAP while breathing spontaneously during instillation. A 5Frenchgamma sterilized multi-access catheter specifically designed to deliver surfactants for Neonates was placed 1-2 cm below the vocal cords by direct laryngoscopy without the use of a Magill forceps. Beractant was used as exogenous natural surfactant, (100mg/kg; 4ml/kg) and administered in two aliquots during 1-3 minutes. Positive pressure inflations were given by a mask and bag only if the infant was apneic or bradycardia develops despite the interruption of the procedure. The surfactant administration catheter was removed after surfactant instillation and nCPAP support was maintained. A second dose of surfactant was administered during the first 3 days of life if more than 40% of FiO2 was needed while on nCPAP with at least 6 cm H2O pressure.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: INSURE
Description: The INSURE technique was performed using Beractant (4ml/kg) after endotracheal intubation. A multi-access catheter for Neonates/Pediatrics designed to deliver surfactants (KimVentTrach Care Technology ®, United Kingdom) was pre-connected to the endotracheal tube and used for surfactant administration without having to disconnect the ventilator. While surfactant was administered all infants were connected to pressure support ventilation modality (PSV) combined with volume guarantee (VG), Dräger ventilator). A tidal volume of 4ml/kg was initially adjusted.~After surfactant administration, all infants were to be extubated, in accordance with our institutional extubation guidelines, if FiO2\< 0.35; for a target Oxygen Saturation (SpO2) of \>90%, and if a consistent respiratory effort was present. Extubation was supported with nCPAP in all patients.
Study: NCT04180345

Intervention type: OTHER
Intervention: Psychometric validation of the questionnaire
Description: Delph Process : expert panel will include HCPs and patients. They will evaluate the relevance of items on a Likert scale (HCPs N = 25 ; Patients N = 25 ) Think aloud interviews (N = 10 patients) Psychometric validation ( N = 200 patients)
Study: NCT00542009

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match CE-326,597 tablets to be administered orally, once daily with morning meal for duration of trial (84 days).
Study: NCT01125995

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: early CCRT
Description: 1. patients will be received with 4 cycles of etoposide 100mg/m2 D1-3 \& Cisplatin 70mg/m2 D1.~2. radiotherapy start from day 1 of 1st chemotherapy cycle and complete 5250cGy/25fraction (daily one fraction, 210cGy).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: late CCRT
Description: 1. patients will be received with 4 cycles of etoposide 100mg/m2 D1-3 \& Cisplatin 70mg/m2 D1.~2. radiotherapy start from day 1 of the third cycle of EP chemotherapy and complete 5250cGy/25fraction (daily one fraction, 210cGy).
Study: NCT00447603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide (+) losartan potassium
Description: losartan/hydrochlorothiazide 12.5mg tablet po qd; for a 4 week study period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide (+) losartan potassium
Description: losartan/hydrochlorothiazide 12.5mg tablet po qd; for a 4 week study period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan potassium
Description: Losartan 50mg titrating up to Losartan 100mg tablet po qd; for a 4 week study period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan potassium
Description: Losartan 50mg titrating up to Losartan 100mg tablet po qd; for a 4 week study period
Study: NCT00542009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CE-326,597 5mg QD
Description: Administered orally, once daily with morning meal for duration of trial (84 days).
Study: NCT00447603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Losartan
Study: NCT04306965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: 30 mg twice daily (BID)
Study: NCT03839862

Intervention type: DRUG
Intervention: TNF-inhibition
Description: Initiation of immunosuppression with any TNF-inhibitor, e.g. infliximab, etanercept or adalimumab

Intervention type: DRUG
Intervention: TNF-inhibition
Description: Initiation of immunosuppression with any TNF-inhibitor, e.g. infliximab, etanercept or adalimumab
Study: NCT04574908

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ViSi device
Description: Mobile patient monitoring system for vital signs.
Study: NCT04574908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ViSi device
Description: Mobile patient monitoring system for vital signs.
Study: NCT04234139

Intervention type: PROCEDURE
Intervention: liver transplant
Description: solid organ transplant

Intervention type: PROCEDURE
Intervention: liver transplant
Description: solid organ transplant

Intervention type: PROCEDURE
Intervention: liver transplant
Description: solid organ transplant
Study: NCT01398969

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fresh FMT
Description: Participants will receive fresh FMT (supernatant of fecal specimen mixed with water) on day 1. If cure is not reached at day 5 (+3) a repeat FMT will be performed

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Frozen-and-Thawed FMT
Description: Participants will receive frozen-and-thawed FMT (supernatant of fecal specimen mixed with water) on day 1. If cure is not reached at day 5 (+3) a repeat FMT will be performed
Study: NCT00521638

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRU-015
Description: Intravenous administration; 400 mg, 700 mg, or 1000 mg; 1x/week dosing for 4 weeks
Study: NCT02657122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 for SAD
Description: SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 5 dose ascending cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally as a single dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for SAD
Description: SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 5 dose ascending cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally as a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 for MAD
Description: MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 4 cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally for a total of 14 days of dosing.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MAD
Description: MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 4 cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally for a total of 14 days of dosing.
Study: NCT03883230

Intervention type: DIAGNOSTIC_TEST
Intervention: GLYWD
Description: As mentioned in the group description, GLYWD is a plastic test tube and a chromatic test that contains two solutions. When combined with a wound exudate and incubated at RT, it will change colour to red if there is a pathological bacterial wound infection present.
Study: NCT01511029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole
Description: 300 mg - Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole
Description: 600 mg Oral Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexpramipexole Placebo
Description: Placebo - Oral Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 400 mg - Oral Tablet
Study: NCT02132182

Intervention type: BIOLOGICAL
Intervention: Blood draw
Description: The patient population for this study will be comprised of individuals who present to clinic with newly diagnosed osteosarcoma with or without infection and without known metastasis to the lung. These patients would have a standard-of-care blood draw. For the study we will be drawing an additional 15-20mL of blood (no additional needle stick).
Study: NCT04650555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO 300 Oral Powder
Description: Amorphous solid dispersion of genistein milled into a powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO 300 Oral Powder
Description: Amorphous solid dispersion of genistein milled into a powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO 300 Oral Powder
Description: Amorphous solid dispersion of genistein milled into a powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO 300 Oral Powder
Description: Amorphous solid dispersion of genistein milled into a powder